GlassScriptPhysician profile
Cynthia Shields
NPI 1588098057
$2,218.57
in general payments reported to CMS, 2019-2025
26 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,643 · 2022: $240 · 2024: $75.74 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $335.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $454.04 | 2021-2025 | Ojjaara |
| Genzyme Corporation | $292.02 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $227.57 | 2021-2025 | Enhertu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.13 | 2021-2022 | |
| Lundbeck LLC | $122.27 | 2021 | |
| Novartis Pharmaceuticals Corporation | $114.44 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $112.73 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $81.13 | 2021 | |
| Merck Sharp & Dohme LLC | $71.60 | 2021-2025 | Keytruda, Lynparza |
| Janssen Pharmaceuticals, INC | $71.25 | 2021 | |
| Pfizer INC. | $60.71 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.99 | 2021-2025 | Iclusig |
| Jazz Pharmaceuticals INC. | $59.20 | 2021 | |
| Celgene Corporation | $53.07 | 2021 | |
| Mylan Specialty L.P. | $30.07 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $27.37 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $25.59 | 2021 | |
| Grifols USA, LLC | $20.75 | 2021 | |
| Exelixis INC. | $19.27 | 2025 | Cabometyx |
| Lilly USA, LLC | $19.19 | 2025 | Verzenio, Jaypirca |
| E.R. Squibb & Sons, L.L.C. | $18.20 | 2021 | |
| Sumitomo Pharma America, INC. | $16.55 | 2025 | Orgovyx |
| Genentech USA, INC. | $16.21 | 2024 | Polivy |
| Puma Biotechnology, INC. | $15.50 | 2025 | |
| Agios Pharmaceuticals, INC. | $15.18 | 2024 | |
| United Therapeutics Corporation | $8.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Shields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.